The FINANCIAL — Pfizer Inc. announced on April 5 top-line results from its first Phase 3 study investigating tofacitinib for the treatment of psoriatic arthritis, Oral Psoriatic Arthritis triaL (OPAL) ...

Please provide your email address to receive an email when new articles are posted on . Patients with RA taking tofacitinib 5 mg did not have elevated risk for cardiovascular events compared with ...

The approach to the treatment of psoriatic arthritis (PsA) has historically drawn from the treatment of rheumatoid arthritis (RA), although the management of the two diseases has begun to diverge in ...

Share on Facebook. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window It's official: full data from a randomized trial evaluating ...

Credit: Getty Images. Results of the ORAL Surveillance study showed a higher risk for major adverse CV events and venous thromboembolism with tofacitinib vs TNFis. The risk for a composite of all ...

(HealthDay News) — Tofacitinib is associated with improvements in nail psoriasis, according to a study published in the the Journal of the American Academy of Dermatology. Joseph F. Merola, MD, from ...

3d ulcerative extensive colitis infection with clipping path. Researchers sought to identify predictors of response or remission in ulcerative colitis after patients received tofacitinib maintenance ...

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for XELJANZ® / XELJANZ® ...